血液病患者感染治疗中应用替考拉宁效果分析  

Efficacy of teicoplanin on infection therapy of patients with hematologic diseases

作　　者：张镇[1] 严丽芳[1] 冯春[1] 杨洁[1] 廖佳[1] 

机构地区：[1]青海红十字医院血液科,青海西宁810000

出　　处：《中华医院感染学杂志》2016年第16期3722-3723,3726,共3页Chinese Journal of Nosocomiology

基　　金：国家自然科学基金资助项目(81000224)

摘　　要：目的研究替考拉宁经验性治疗中性粒细胞缺乏症及细菌感染患者的疗效,为临床治疗提供参考依据。方法选取2013年6月-2015年6月40例医院中性粒细胞缺乏症患者,经验性给予替考拉宁治疗,评价其临床疗效,数据采用SPSS 17.0软件进行统计分析。结果通过替考拉宁治疗后中性粒细胞缺乏症患者持续伴随有中性粒细胞数量<1 000/μL有效治疗率为77.5%;与药物相关的不良反应发生率仅为7.5%,为轻度不良反应,耐受性好;替考拉宁的每日剂量或持续时间会产生轻微的不良反应。结论替考拉宁有足够的临床疗效,是一种安全的治疗细菌感染的血液病及中性粒细胞缺乏症患者的理想药物。OBJECTIVE To investigate the efficacy of teicoplanin on empirical therapy of patients with neutropenia and bacterial infection,so as to provide references for clinical treatment.METHODS A total of 40 cases of hospital neutropenic patients administered teicoplanin from Jun.2013 to Jun.2015 were selected,and the clinical efficacy were evaluated.The data were analyzed by SPSS 17.0.RESULTS The sustained accompanied neutrophil counts of the neutropenia patients treated by teicoplanin were 〈1000/μl,and the effective treatment rate was 77.5%.Drug-related adverse reactions rate was 7.5%,which were mild adverse reactions and well tolerated.Daily dose or duration of teicoplanin would have slight adverse reactions.CONCLUSIONTeicoplanin has sufficient clinical efficacy,and is a kind of safe drug for treatment of bacterial infection of patients with hematologic diseases and neutropenia.

关 键 词：替考拉宁 中性粒细胞缺乏症 血液病 细菌感染 

分 类 号：R552[医药卫生—血液循环系统疾病]